Ovarian Cancer|Inhibitors Agonists Modulators Antagonists|HmoBio.com

Request The Product List ofOvarian Cancer Ovarian Cancer

Ovarian cancer is a group of diseases that originates in the ovaries, or in the related areas of the fallopian tubes and the peritoneum. Women have two ovaries that are located in the pelvis, one on each side of the uterus. The ovaries make female hormones and produce eggs. Women have two fallopian tubes that are a pair of long, slender tubes on each side of the uterus. Eggs pass from the ovaries through the fallopian tubes to the uterus. The peritoneum is the tissue lining that covers organs in the abdomen.

When ovarian cancer is found in its early stages, treatment works best. Ovarian cancer often causes signs and symptoms, so it is important to pay attention to your body and know what is normal for you. Symptoms may be caused by something other than cancer, but the only way to know is to see your doctor, nurse, or other health care professional.

Some mutations (changes in genes) can raise your risk for ovarian cancer. Mutations in the breast cancer susceptibility genes 1 and 2 (BRCA1 and BRCA2), and those associated with Lynch syndrome, raise ovarian cancer risk.

Ovarian cancers come in a variety of different tumor types. The most common tumor type is high-grade serous carcinoma, occurring in about 70% of ovarian cancer cases.

Cat. No.	Product Name	CAS No.	Information
H9346	Pafolacianine sodium	1628858-03-6	Pafolacianine(OTL38) is a folate-indole-cyanine green-like conjugate to folate receptor alpha (FRa).Pafolacianine(OTL38)is comprised of the vitamin folic acid conjugated to an indocyanine green-like near infrared dye termed S0456; Pafolacianine(OTL38) was developed in order to detect folate receptor positive lesions in ovarian cancer patients using an investigational camera imaging system.
H9345	Pafolacianine	1628423-76-6	Pafolacianine(OTL38) is a folate-indole-cyanine green-like conjugate to folate receptor alpha (FRa).Pafolacianine(OTL38)is comprised of the vitamin folic acid conjugated to an indocyanine green-like near infrared dye termed S0456; Pafolacianine(OTL38) was developed in order to detect folate receptor positive lesions in ovarian cancer patients using an investigational camera imaging system.
H9279	SOR-C13	1187852-48-7	SOR-C13, is a novel, short, synthetic peptide,potent TRPV6 Calcium Channel Inhibitor.
H8882	Senaparib	1401682-78-7	Senaparib (IMP4297) is a novel highly potent and selective oral PARP1/2 inhibitor with strong antitumor activity in preclinical studies.
H8297	LY2940680	1258861-20-9	LY2940680 (Taladegib) is potent Smoothened (SMO) receptor antagonist, potently inhibits Hedgehog (Hh) signaling with IC50 of 6.3 nM in Gli-luc reporter assyas; inhibits medulloblastoma cell proliferation isolated from Ptch+/–p53–/– mice with IC50 of 43.5 nM; demonstrates anti-tumor activity in vivo with advanced basal cell carcinoma (BCC) and other malignancies.
H8131	Vatalanib free base	212141-54-3	A potent, orally available class III receptor tyrosine kinases inhibitor with IC50 of <1 uM for VEGFR, Flt-1, KDR and PDGFRβ; shows no activity against EGFR, FGFR-1, c-Met, and Tie-2, or c-Src, c-Abl, and PKC-α; blocks the VEGF-induced receptor autophosphorylation in CHO cells ectopically expressing the KDR receptor with IC50 of 34 nM; inhibits EGF and PDGF-induced angiogenesis in a growth factor implant model (25-100 mg/kg).
H8130	Vatalanib	212141-51-0	A potent, orally available class III receptor tyrosine kinases inhibitor with IC50 of <1 uM for VEGFR, Flt-1, KDR and PDGFRβ; shows no activity against EGFR, FGFR-1, c-Met, and Tie-2, or c-Src, c-Abl, and PKC-α; blocks the VEGF-induced receptor autophosphorylation in CHO cells ectopically expressing the KDR receptor with IC50 of 34 nM; inhibits EGF and PDGF-induced angiogenesis in a growth factor implant model (25-100 mg/kg).
H8093	Cediranib maleate	857036-77-2	A highly potent, orally bioavailable, pan-VEGFR inibitor with IC50 of 1, 5, 3 nM for VEGFR1, 2, 3, respectively; also inhibits c-Kit and PDGFRβ with IC50 of 2 and 5 nM, >36-fold selectivity over PDGFR-α, >1000-fold over Flt-3 and EGFR; inhibits VEGF-stimulated proliferation and KDR phosphorylation with IC50 of 0.4 and 0.5 nM in human umbilical vein endothelial cells; inhibits angiogenesis, neovascular survival and tumor growth in vivo.
H8092	Cediranib	288383-20-0	A highly potent, orally bioavailable, pan-VEGFR inibitor with IC50 of 1, 5, 3 nM for VEGFR1, 2, 3, respectively; also inhibits c-Kit and PDGFRβ with IC50 of 2 and 5 nM, >36-fold selectivity over PDGFR-α, >1000-fold over Flt-3 and EGFR; inhibits VEGF-stimulated proliferation and KDR phosphorylation with IC50 of 0.4 and 0.5 nM in human umbilical vein endothelial cells; inhibits angiogenesis, neovascular survival and tumor growth in vivo.
H7430	LY2228820 dimesylate	862507-23-1	LY2228820 dimesylate (Ralimetinib) is a potent, selective, orally available inhibitor p38 MAPK with IC50 of 5.3 and 3.2 nM for p38α and p38β, respectively; potently and selectively inhibits phosphorylation of MK2 (Thr334) in anisomycin-stimulated HeLa cells and mouse RAW264.7 macrophages (IC50=35.3 nM), with no changes in phosphorylation of p38α MAPK, JNK, ERK1/2, c-Jun, ATF2, or c-Myc; also reduces TNF-α secretion by LPS/IFN-γ–stimulated macrophages with IC50 of 6.3 nM; produces significant tumor growth delay in multiple in vivo cancer models (melanoma, non-small cell lung cancer, ovarian, glioma, myeloma, breast).

Select Your Country or Region

Request The Product List ofOvarian Cancer Ovarian Cancer

Request The Product List

* Indicates a Required FieldYour information is safe with us.